Notably, based on the outcomes of the Impower010 trial, atezolizumab has emerged as the first ICI to receive approval from the United States Food and Drug Administration (FDA) for use as an adjuvant therapy in stage II-IIIA resectable NSCLC patients with a PD-L1 expression level of ≥1% (7). This evidence concerns the gene CD274 and non-small cell lung carcinoma.